熱門資訊> 正文
Scinai股价在银屑病药物临床前研究中飙升54%
2024-07-15 23:08
- Scinai Immunotherapeutics (NASDAQ:SCNI) stock soared 54% in Monday morning trading after the Israeli biotech reported positive results from a pre-clinical study of its NanoAb therapy candidate in the treatment of plaque psoriasis.
- The study showed inflammatory markers in modified mice treated with the NanoAb product were similar to those of two comparator drugs. As opposed to other therapies used to treat the condition, NanoAb, anti IL-17A/F VHH antibody fragment, is administered directly into skin lesions via a short needle, according to a statement.
- Scinai intends to conduct a follow-on in vivo animal study in late 2024, with a first-in-human clinical trial expected to begin in late 2025.
More on Scinai Immunotherapeutics
- Financial information for Scinai Immunotherapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
